Coronavirus (COVID-19) Update - We are reopening slowly while keeping your safety in mind.
Click here to learn more.
The goal of this study is to evaluate the safety and efficacy of lebrikizumab compared with placebo in patients with moderate-to-severe atopic dermatitis (AD). The dose-response of lebrikizumab in patients will also be measured. Patients with moderate-to-severe AD will be enrolled into this 32-week study. Patients will be seen every 2 weeks, will receive all study drug injections in the clinic, and be evaluated for safety and efficacy through Week 16. A safety follow-up visit will occur at Week 24 and a follow-up phone call will occur at Week 32.
Dr. Alison Ehrlich, MD, MHS/Dermatology